Cargando…
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
Autores principales: | Dintsios, Charalabos-Markos, Chernyak, Nadja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021141/ https://www.ncbi.nlm.nih.gov/pubmed/34964091 http://dx.doi.org/10.1007/s40258-021-00712-x |
Ejemplares similares
-
Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
por: Ruof, Jörg, et al.
Publicado: (2013) -
“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations
por: Staab, Thomas R., et al.
Publicado: (2018) -
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
por: Gandjour, Afschin
Publicado: (2023) -
Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020) -
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
por: Büssgen, Melanie, et al.
Publicado: (2023)